Two incretin pathways. One physician watching both.
Compounded tirzepatide injection built around dual GIP and GLP-1 receptor biology with clinician-directed dosing and follow-up.
Compounded semaglutide and tirzepatide are not FDA-approved products. They are prescribed by licensed clinicians based on individual clinical evaluation and prepared by a licensed 503A pharmacy. Not all patients qualify.
About 10 minutes. No charge unless your clinician approves.
Why one pathway when the molecule has two?
Tirzepatide is a dual agonist: it activates both the GIP and GLP-1 receptors, two incretin pathways your gut already uses to manage appetite and glucose after meals. Working together, they slow gastric emptying, moderate hunger signaling in the brain, and support the insulin response that governs how your body handles fuel. Same biology, two levers instead of one.
The compounded program is clinician-directed end to end. Dosing starts low and titrates on a schedule built around your response and tolerability, adjusted through monthly provider check-ins rather than a fixed calendar. If you have tried single-pathway GLP-1 therapy before, your provider weighs that history when deciding whether the dual-pathway option makes sense for you.
Tirzepatide activates both the GIP and GLP-1 receptors, giving your clinician a dual-pathway option with dosing and follow-up built around your individual response.
Read the evidence →For when appetite is biology, not a character test.
The Biology-First Patient
Your nutrition plan is not a mystery and your effort is not the missing ingredient. You want a clinician to evaluate the appetite and glucose signaling underneath the struggle.
The Prior GLP-1 Patient
You have experience with a single-pathway incretin medication and want the next decision made from that history. Tirzepatide gives your provider a different receptor profile to consider.
The Long-Game Planner
You are not looking for a dramatic month. You want a medical plan that can be reviewed, adjusted, and eventually reconsidered as your goals and health change.
Compounded tirzepatide is not an FDA-approved drug product. Candidacy, dose, and how it sequences with anything else you take are determined by a licensed provider from your full assessment.
This might not be the right fit if:
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy, planned pregnancy, or breastfeeding
- Severe gastrointestinal disease, including gastroparesis
- Type 1 diabetes or insulin-dependent regimens without specialist oversight
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Tirzepatide, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Licensed clinician review of your history, medications, goals, and prior incretin use
- Individual decision on whether compounded tirzepatide is appropriate
- Preparation by a licensed 503A pharmacy if prescribed
- Clinician-directed treatment changes based on response and tolerability
- Ongoing review of the broader metabolic plan
Compounded semaglutide and tirzepatide are not FDA-approved products. They are prescribed by licensed clinicians based on individual clinical evaluation and prepared by a licensed 503A pharmacy. Not all patients qualify.
More in Metabolic.
Semaglutide
A clinician on the other end of every dose.
Compounded semaglutide injection with clinician review, pharmacy fulfillment, shipping, and follow-up inside one care model. (Contains semaglutide.)
Semaglutide + B12 Microdose
A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale. (Contains semaglutide and vitamin B12.)
Tirzepatide + B12 Microdose
Dual-pathway biology at a lower starting scale.
A lower-dose compounded tirzepatide and B12 prescription that keeps dual-receptor biology inside clinician-led care. (Contains tirzepatide and vitamin B12.)
What the research shows
Tirzepatide is one peptide that activates both the GIP and GLP-1 receptors.
The detail
Tirzepatide is a single peptide that binds to and activates both the GIP receptor and the GLP-1 receptor, the targets of the two native incretin hormones.1
GIP and GLP-1 are gut peptides that produce the incretin effect after nutrient intake.
The detail
GIP and GLP-1 are gut peptides secreted after nutrient intake, GIP from K cells of the upper intestine and GLP-1 from L cells of the lower intestine, and together they produce the incretin effect, the larger insulin secretory response to oral than to intravenous glucose; GLP-1 is also glucagonostatic.2
Labeling says tirzepatide raises insulin, lowers glucagon and delays gastric emptying.
The detail
Approved tirzepatide labeling states that the molecule enhances first- and second-phase insulin secretion and reduces glucagon, both in a glucose-dependent manner, and that it delays gastric emptying, an effect largest after the first dose that diminishes over time.1
Labeling calls GLP-1 an appetite regulator; the GIP contribution rests on animal studies.
The detail
The same class of labeling describes GLP-1 as a physiological regulator of appetite and caloric intake, notes that GIP and GLP-1 receptors are found in areas of the brain involved in appetite regulation, and attributes the further contribution of GIP to food-intake regulation to nonclinical studies, with distribution to appetite-related brain regions shown in animal studies.3
A five-day half-life is what enables once-weekly dosing, not any outcome.
The detail
For pharmacokinetics, labeling attributes the dosing interval to molecular design rather than to any outcome: a C20 fatty diacid enables albumin binding, the molecule is described as highly bound to plasma albumin, and the elimination half-life of approximately five days is described as enabling once-weekly dosing, with steady state reached after four weeks of once-weekly administration.1
What it does not show
A compounded preparation is not an FDA-approved drug product.
The detail
A compounded preparation is not an FDA-approved drug product, and FDA does not verify the safety, effectiveness or quality of a compounded drug before it is marketed.4
Everything above describes how the molecule works, not what any trial measured.
The detail
Every statement above is drawn from the clinical pharmacology section of approved labeling, a section separate from the clinical studies section of the same document. This block deliberately describes how the molecule works and does not report what any trial measured.1
Dual agonism is a statement about receptor binding, not a claim of superior results.
The detail
Dual agonism means one molecule occupies two incretin receptors, a property characterized in vitro through receptor-occupancy analysis and cell signalling assays. It is a statement about receptor binding rather than a claim of results superior to agonism at the GLP-1 receptor alone.5
The GIP role in food intake was established in mice, not in humans.
The detail
The central nervous system role of GIP receptor signalling in the control of food intake was established in mice, and rodent findings of that kind do not establish human outcomes.6
None of the sources above evaluated a compounded preparation.
The detail
Approved-product labeling describes the pharmacokinetics and quality attributes of that finished product. It does not describe the exposure, potency or content of a preparation compounded to an individual prescription, and none of the sources above evaluated such a preparation.4
- FDA-approved tirzepatide injection prescribing information, sections…DailyMed
- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018.
- FDA-approved tirzepatide injection prescribing information, section…DailyMed
- FDA, Compounding and the FDA: Questions and Answers.FDA
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor… JCI Insight. 2020. In vitro receptor pharmacology.
- Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body… Cell Metab. 2021.e5. Mouse study.
FDA-approved tirzepatide products carry a boxed warning about thyroid C-cell tumors observed in rats; whether tirzepatide causes these tumors in humans is unknown. That warning is why a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication, and why pancreatitis history, pregnancy plans, significant gastrointestinal disease, and any glucose-lowering medication are reviewed before prescribing.
Do not use if you have
- A personal or family history of medullary thyroid carcinoma or MEN 2
Serious risks
- Pancreatitis
- Gallbladder disease
- Severe gastrointestinal reactions
- Kidney injury related to dehydration
- Hypoglycemia when tirzepatide is used with insulin or insulin secretagogues
Commonly reported
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
Because it is a compounded preparation
- This preparation is compounded rather than an FDA-approved finished drug product, so it has no safety database of its own
The effects patients report most often are gastrointestinal, most often during titration. The important risks in tirzepatide labeling are listed here. The prescribing judgment stays with your clinician.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Provider review, your prescription if approved, pharmacy fulfillment, shipping, monthly check-ins, and direct messaging with your care team. There are no separate consult fees. If your provider recommends supportive medication, they will discuss that with you before anything changes on your bill.
Semaglutide acts on the GLP-1 receptor alone. Tirzepatide engages GLP-1 and GIP together, two incretin pathways involved in appetite and glucose regulation. Which molecule suits you depends on your history, goals, and tolerability, and that is a decision your provider makes with you at assessment, not one you have to make alone.
The most common are gastrointestinal: nausea, constipation, diarrhea, and reflux, most often during titration and typically easing as your body adjusts. Your provider can slow the schedule, adjust your dose, or prescribe supportive medication such as ondansetron. Anything persistent or severe goes straight to your care team.